Sinopharm Group Co. Ltd.
SHTDFOTCHealthcare● Active
$2.30
+$0.01(+0.44%)
Market Cap$7.2B
P/E Ratio—
52W High$2.7
52W Low$2.11
Sinopharm Group Co. Ltd. (SHTDF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SHTDF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $14.80B | $14.00B | $19.51B | $18.56B | $17.00B |
| Depreciation & Amort. | $4.29B | $4.73B | $4.43B | $4.17B | $3.92B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($2.75B) | ($13.24B) | ($3.86B) | ($2.07B) | ($12.10B) |
| Net Cash from Operations | $14.14B | $11.55B | $17.17B | $20.96B | $9.31B |
| Investing Activities | |||||
| Capital Expenditure | ($1.62B) | ($1.97B) | ($2.34B) | ($2.42B) | ($2.26B) |
| Purchases of Investments | $0.00B | $0.00B | ($0.03B) | ($0.10B) | ($0.07B) |
| Sales of Investments | $0.02B | $0.00B | $0.05B | $0.21B | $0.30B |
| Net Cash from Investing | ($0.96B) | ($3.75B) | ($0.94B) | ($3.59B) | ($1.27B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | ($2.12B) | ($2.71B) | ($2.56B) | ($2.34B) | ($2.15B) |
| Debt Issued / Repaid | ($10.91B) | ($9.94B) | $2.50B | $4.75B | ($4.79B) |
| Net Cash from Financing | ($18.69B) | ($17.29B) | ($7.64B) | ($5.69B) | ($14.69B) |
| Free Cash Flow | |||||
| Free Cash Flow | $12.52B | $9.58B | $14.84B | $18.55B | $7.05B |
| FCF Margin %(computed) | 2.23% | 1.64% | 2.49% | 3.36% | 1.35% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CNY · B
Explore more Sinopharm Group Co. Ltd. data
About Sinopharm Group Co. Ltd. (SHTDF) Cash Flow Statement
Sinopharm Group Co. Ltd. generated operating cash flow of $14.14B and free cash flow of $12.52B for 2025 — a FCF margin of 2.23%. Capital expenditure was ($1.62B).
Frequently asked questions
SHTDF · 4 questionsSinopharm Group Co. Ltd. generated free cash flow of $12.52B for 2025, up 30.7% year-over-year.
SHTDF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10